Return-to-Play Decisions in Athletes with Cardiac Conditions: Guidelines and Considerations

  • Christine E. Lawless


Clinicians who treat the more than 20 million competitive and recreational athletes in the USA are confronted by a variety of return-to-play (RTP) decisions [1, 2]. The main objective of these decisions is to prevent sudden cardiac death (SCD) during sports participation, while allowing all individuals to experience the benefits of exercise and physical activity.


Sudden Cardiac Death Aortic Stenosis Bicuspid Aortic Valve Sport Participation Mitral Valve Prolapse 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Street and Smith’s Sports Business Daily. Team sports participation in the US up for organized leagues. September 10, 2008; Accessed March 18, 2009. Web Page Available at:
  2. 2.
    Lawless CE. Return-to-play decisions in athletes with cardiac conditions. Physician Sportsmed. 2009;37:80–91.CrossRefGoogle Scholar
  3. 3.
    Maron BJ, Thompson PD, Ackerman MJ, et al. Recommendations and considerations related to preparticipation screening for cardiovascular abnormalities in competitive athletes: 2007 update: a scientific statement from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism: endorsed by the American College of Cardiology Foundation. Circulation. 2007;115:1643–1655.PubMedCrossRefGoogle Scholar
  4. 4.
    Maron BJ, Zipes DP. Introduction: eligibility recommendations for competitive athletes with cardiovascular abnormalities – general considerations. J Am Coll Cardiol. 2005;45:1318–1321.PubMedCrossRefGoogle Scholar
  5. 5.
    Pelliccia A, Fagard R, Bjornstad HH, et al. Recommendations for competitive sports participation in athletes with cardiovascular disease: a consensus document from the Study Group of Sports Cardiology of the Working Group of Cardiac Rehabilitation and Exercise Physiology and the Working Group of Myocardial and Pericardial Diseases of the European Society of Cardiology. Eur Heart J. 2005;26:1422–1445.PubMedCrossRefGoogle Scholar
  6. 6.
    Pelliccia A, Corrado D, Bjornstad HH, et al. Recommendations for participation in competitive sport and leisure-time physical activity in individuals with cardiomyopathies, myocarditis and pericarditis. Eur J Cardiovasc Prev Rehabil. 2006;13:876–885.PubMedCrossRefGoogle Scholar
  7. 7.
    Maron BJ, Chaitman BR, Ackerman MJ, et al. Recommendations for physical activity and recreational sports participation for young patients with genetic cardiovascular diseases. Circulation. 2004;109:2807–2816.PubMedCrossRefGoogle Scholar
  8. 8.
    Estes NA 3rd, Link MS, Cannom D, et al. Report of the NASPE policy conference on arrhythmias and the athlete. J Cardiovasc Electrophysiol. 2001;12:1208–1219.PubMedCrossRefGoogle Scholar
  9. 9.
    Maron BJ, Araujo CG, Thompson PD, et al. Recommendations for preparticipation screening and the assessment of cardiovascular disease in masters athletes: an advisory for healthcare professionals from the working groups of the World Heart Federation, the International Federation of Sports Medicine, and the American Heart Association Committee on Exercise, Cardiac Rehabilitation, and Prevention. Circulation. 2001;103:327–334.PubMedCrossRefGoogle Scholar
  10. 10.
    Pelliccia A, Zipes DP, Maron BJ. Bethesda Conference #36 and the European Society of Cardiology Consensus Recommendations revisited a comparison of U.S. and European criteria for eligibility and disqualification of competitive athletes with cardiovascular abnormalities. J Am Coll Cardiol. 2008;52:1990–1996.PubMedCrossRefGoogle Scholar
  11. 11.
    Thompson PD, Franklin BA, Balady GJ, et al. Exercise and acute cardiovascular events placing the risks into perspective: a scientific statement from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism and the Council on Clinical Cardiology. Circulation. 2007;115:2358–2368.PubMedCrossRefGoogle Scholar
  12. 12.
    Thompson PD, Funk EJ, Carleton RA, Sturner WQ. Incidence of death during jogging in Rhode Island from 1975 through 1980. JAMA. 1982;247:2535–2538.PubMedCrossRefGoogle Scholar
  13. 13.
    Maron BJ, Shen WK, Link MS, et al. Efficacy of implantable cardioverter–defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy. N Engl J Med. 2000;342:365–373.PubMedCrossRefGoogle Scholar
  14. 14.
    Lampert R, Cannom D, Olshansky B. Safety of sports participation in patients with implantable cardioverter defibrillators: a survey of heart rhythm society members. J Cardiovasc Electrophysiol. 2006;17:11–15.PubMedCrossRefGoogle Scholar
  15. 15.
    Lawless CE. Implantable cardioverter defibrillators in athletes: rationale for use and issues surrounding return to play. Curr Sports Med Rep. 2008;7:86–92.PubMedGoogle Scholar
  16. 16.
    Lawless CE, Lampert R, Olshansky B, Cannom D. Safety and efficacy of implantable defibrillators and automatic external defibrillators in athletes: results of a nationwide survey among AMSSM members. Clin J Sports Med. 2005;15:386–391.CrossRefGoogle Scholar
  17. 17.
    Moss AJ, Zareba W, Hall WJ, et al. Effectiveness and limitations of beta-blocker therapy in congenital long-QT syndrome. Circulation. 2000;101:616–623.PubMedCrossRefGoogle Scholar
  18. 18.
    Priori SG, Napolitano C, Schwartz PJ, et al. Association of long QT syndrome loci and cardiac events among patients treated with beta-blockers. JAMA. 2004;292:1341–1344.PubMedCrossRefGoogle Scholar
  19. 19.
    Vanhees L, Defoor JG, Schepers D, et al. Effect of bisoprolol and atenolol on endurance exercise capacity in healthy men. J Hypertens. 2000;18:35–43.PubMedCrossRefGoogle Scholar
  20. 20.
    Savage DD, Seides SF, Clark CE, et al. Electrocardiographic findings in patients with obstructive and nonobstructive hypertrophic cardiomyopathy. Circulation. 1978;58:402–408.PubMedCrossRefGoogle Scholar
  21. 21.
    Thompson PD, Buchner D, Pina IL, et al. Exercise and physical activity in the prevention and treatment of atherosclerotic cardiovascular disease: a statement from the Council on Clinical Cardiology (Subcommittee on Exercise, Rehabilitation, and Prevention) and the Council on Nutrition, Physical Activity, and Metabolism (Subcommittee on Physical Activity). Circulation. 2003;107:3109–3116.PubMedCrossRefGoogle Scholar
  22. 22.
    Passino C, Severino S, Poletti R, et al. Aerobic training decreases B-type natriuretic peptide expression and adrenergic activation in patients with heart failure. J Am Coll Cardiol. 2006;47:1835–1839.PubMedCrossRefGoogle Scholar
  23. 23.
    Pina IL, Apstein CS, Balady GJ, et al. Exercise and heart failure: a statement from the American Heart Association Committee on exercise, rehabilitation, and prevention. Circulation. 2003;107:1210–1225.PubMedCrossRefGoogle Scholar
  24. 24.
    O’Connor CM, Whellan DJ, Lee KL, et al. Efficacy and safety of exercise training in patients with chronic heart failure: HF-ACTION randomized controlled trial. JAMA. 2009;301:1439–1450.PubMedCrossRefGoogle Scholar
  25. 25.
    Maron BJ. Sudden death in young athletes. N Engl J Med. 2003;349:1064–1075.PubMedCrossRefGoogle Scholar
  26. 26.
    Corrado D, Thiene G, Nava A, Rossi L, Pennelli N. Sudden death in young competitive athletes: clinicopathologic correlations in 22 cases. Am J Med. 1990;89:588–596.PubMedCrossRefGoogle Scholar
  27. 27.
    Thiene G, Nava A, Corrado D, Rossi L, Pennelli N. Right ventricular cardiomyopathy and sudden death in young people. N Engl J Med. 1988;318:129–133.PubMedCrossRefGoogle Scholar
  28. 28.
    Angelini P, Velasco JA, Flamm S. Coronary anomalies: incidence, pathophysiology, and clinical relevance. Circulation. 2002;105:2449–2454.PubMedCrossRefGoogle Scholar
  29. 29.
    Mannix, C. The cardiac kid. Sports Illustrated. March 20, 2006; Accessed May 3, 2010. Web Page Available at:
  30. 30.
    Calkins H, Yong P, Miller JM, et al. Catheter ablation of accessory pathways, atrioventricular nodal reentrant tachycardia, and the atrioventricular junction: final results of a prospective, multicenter clinical trial. The Atakr Multicenter Investigators Group. Circulation. 1999;99:262–270.PubMedCrossRefGoogle Scholar
  31. 31.
    Naccarelli GV, Shih HT, Jalal S. Catheter ablation for the treatment of paroxysmal supraventricular tachycardia. J Cardiovasc Electrophysiol. 1995;6:951–961.PubMedCrossRefGoogle Scholar
  32. 32.
    Klein GJ, Bashore TM, Sellers TD, Pritchett EL, Smith WM, Gallagher JJ. Ventricular fibrillation in the Wolff–Parkinson–White syndrome. N Engl J Med. 1979;301:1080–1085.PubMedCrossRefGoogle Scholar
  33. 33.
    Pappone C, Santinelli V, Rosanio S, et al. Usefulness of invasive electrophysiologic testing to stratify the risk of arrhythmic events in asymptomatic patients with Wolff–Parkinson–White pattern: results from a large prospective long-term follow-up study. J Am Coll Cardiol. 2003;41:239–244.PubMedCrossRefGoogle Scholar
  34. 34.
    Pappone C, Santinelli V, Manguso F, et al. A randomized study of prophylactic catheter ablation in asymptomatic patients with the Wolff–Parkinson–White syndrome. N Engl J Med. 2003;349:1803–1811.PubMedCrossRefGoogle Scholar
  35. 35.
    Biffi A, Pelliccia A, Verdile L, et al. Long-term clinical significance of frequent and complex ventricular tachyarrhythmias in trained athletes. J Am Coll Cardiol. 2002;40:446–452.PubMedCrossRefGoogle Scholar
  36. 36.
    Cole CR, Marrouche NF, Natale A. Evaluation and management of ventricular outflow tract tachycardias. Card Electrophysiol Rev. 2002;6:442–447.PubMedCrossRefGoogle Scholar
  37. 37.
    Lerman BB, Stein KM, Markowitz SM, Mittal S, Slotwiner DJ. Ventricular arrhythmias in normal hearts. Cardiol Clin. 2000;18:265–291.PubMedCrossRefGoogle Scholar
  38. 38.
    Maruyama M, Tadera T, Miyamoto S, Ino T. Demonstration of the reentrant circuit of verapamil-sensitive idiopathic left ventricular tachycardia: direct evidence for macroreentry as the underlying mechanism. J Cardiovasc Electrophysiol. 2001;12:968–972.PubMedCrossRefGoogle Scholar
  39. 39.
    Nogami A. Idiopathic left ventricular tachycardia: assessment and treatment. Card Electrophysiol Rev. 2002;6:448–457.PubMedCrossRefGoogle Scholar
  40. 40.
    Ouyang F, Cappato R, Ernst S, et al. Electroanatomic substrate of idiopathic left ventricular tachycardia: unidirectional block and macroreentry within the purkinje network. Circulation. 2002;105:462–469.PubMedCrossRefGoogle Scholar
  41. 41.
    Jacobs W, Chamoun A, Stouffer GA. Mitral valve prolapse: a review of the literature. Am J Med Sci. 2001;321:401–410.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  1. 1.Sports Cardiology Consultants, LLC, Clinical Associate Faculty, Major League Soccer Team Physician, US Figure Skating World TeamsUniversity of Chicago Consulting CardiologistChicagoUSA

Personalised recommendations